BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6754771)

  • 1. Tilorone hydrochloride in the treatment of T cell lymphoproliferative cutaneous disease.
    Crotty CP; Winkelmann RK
    J Am Acad Dermatol; 1982 Oct; 7(4):468-77. PubMed ID: 6754771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell receptor gene rearrangement analysis: cutaneous T cell lymphoma, peripheral T cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders.
    Zelickson BD; Peters MS; Muller SA; Thibodeau SN; Lust JA; Quam LM; Pittelkow MR
    J Am Acad Dermatol; 1991 Nov; 25(5 Pt 1):787-96. PubMed ID: 1839392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous T cell lymphomas: mycosis fungoides, Sézary syndrome and lymphomatoid papulosis--Part I.
    Safai B
    Clin Bull; 1977; 7(3):91-7. PubMed ID: 308870
    [No Abstract]   [Full Text] [Related]  

  • 4. Photochemotherapy in cutaneous T cell lymphoma and parapsoriasis en plaques. Long-term follow-up in forty-three patients.
    Rosenbaum MM; Roenigk HH; Caro WA; Esker A
    J Am Acad Dermatol; 1985 Oct; 13(4):613-22. PubMed ID: 3878369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of parapsoriasis en plaques, mycosis fungoides, and Sézary's syndrome with trioxsalen baths followed by ultraviolet light.
    Fischer T; Skogh M
    Acta Derm Venereol; 1979; 59(2):171-3. PubMed ID: 84498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine in the treatment of cutaneous T cell lymphoma.
    Street ML; Muller SA; Pittelkow MR
    J Am Acad Dermatol; 1990 Dec; 23(6 Pt 1):1084-9. PubMed ID: 2273106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
    Janiga J; Kentley J; Nabhan C; Abdulla F
    Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
    Dugas-Breit S; Schulze HJ; Hallermann C
    J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sézary syndrome in an 11-year-old girl.
    Meister L; Duarte AM; Davis J; Perez JL; Schachner LA
    J Am Acad Dermatol; 1993 Jan; 28(1):93-5. PubMed ID: 8425978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathologic studies in Sézary syndrome and erythrodermic mycosis fungoides: a comparison with benign forms of erythroderma.
    Sentis HJ; Willemze R; Scheffer E
    J Am Acad Dermatol; 1986 Dec; 15(6):1217-26. PubMed ID: 2948972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments in cutaneous lymphoproliferative disorders.
    Slater DN
    J Pathol; 1987 Sep; 153(1):5-19. PubMed ID: 3312549
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
    Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
    Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
    Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
    J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
    Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
    Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Zic JA
    Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening tests for Sezary cells in cutaneous T-cell lymphomas.
    Newton JA; Guthrie DL; Westwood NB; Pearson TC; Camplejohn RS; Smith N
    Clin Lab Haematol; 1986; 8(2):109-14. PubMed ID: 3488168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. State of the art therapy of mycosis fungoides and Sézary syndrome.
    Kemme DJ; Bunn PA
    Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
    Schappell DL; Alper JC; McDonald CJ
    Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.